MedPath

Giessen Pulmonary Hypertension in Lung Cancer Registry

Recruiting
Conditions
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions
Other: All lung cancer patients.
Registration Number
NCT04467333
Lead Sponsor
University of Giessen
Brief Summary

The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Patient with lung cancer at the University of Giessen lung Cancer Center.
Exclusion Criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
All lung cancer patientsAll lung cancer patients.There will not be an intervention.
Primary Outcome Measures
NameTimeMethod
sPAP values measured via Echocardiography.2 years

systolic pulmonary artery pressure (sPAP) measured in millimetre of mercury (mmHg).

Measurements of the pulmonary artery diameter (PA) and ascending aorta (AA) diameter measured via computed tomography scan. PA and AA will be measured in millimeters.2 years

PA and AA will be combined to report the PA/AA quotient as indicator for pulmonary hypertension in all lung cancer patients. With a cut off value of ≥ 1 defining pulmonary hypertension.

6 Minute Walk Test in meters.2 years

The 6 minute walk test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance in meters covered over a time of 6 minutes is used as the outcome.

Modified Medical Research Council Scale (mMRC).2 years

Scores on the mMRC reach from 0-4, with higher scores indicating greater dyspnea.

chronic obstructive pulmonary disease assessment test (CAT).2 years

Scores on the CAT reach from 0-40, with higher scores indicating greater dyspnea.

Overall Survival and Progression Free Survival measured in days.2 years

Overall Survival and Progression free survival in days will be determined by Kaplan-Meier Analysis .Measuared in (st) (time from diagnosis to death)

Pulmonary function test measured via Spirometry.2 years

vital capacity, total lung capacity, forced expiratory volume in one second, functional vital capacity, diffusing capacity for carbon monoxide, arterial partial pressure of oxygen; all measured as % of predicted normal values.

Body mass index.2 years

weight and height will be combined to report BMI in kg/m\^2.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University hospital Giessen

🇩🇪

Gießen, Hessen, Germany

© Copyright 2025. All Rights Reserved by MedPath